Reducing Causes of Employee Accidents

Cedars-Sinai was one of 12 among 172 adult transplant centers in the U.S. with a one-year patient post-transplant survival rate above the expected outcome. In 2024, the survival rate for Cedars-Sinai was 90% versus the expected rate of 68% to 83%.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks associated with taking the medication.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Regulators have set a goal of Aug. 12, 2025, for brensocatib to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung disease.